Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 23, 2009

Xencor Signs Antibody Optimization Deal with CSL

  • CSL inked an agreement to use Xencor’s XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies. In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.

    During the research phase of the collaboration, Xencor will provide CSL the ability to use this technology across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates that incorporate XmAb technology into development and ultimately commercialization.

  • You’re all set! Thank you for subscribing to GEN Highlights.